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Background: Ischemic stroke is a devastating condition, with metabolic derangement and 
persistent inflammation enhancing the initial insult of ischaemia. Recombinant tissue plasmino-
gen remains the only effective treatment but limited as therapy must commence soon after the 
onset of symptoms.
Purpose: We investigated whether acetate, which modulates many pathways including inflam-
mation, may attenuate brain injury in stroke. As acetate has a short blood half-life and high 
amounts irritate the gastrointestinal tract, acetate was administered encapsulated in a liposomal 
nanoparticle (liposomal-encapsulated acetate, LITA).
Methods: Transient ischemia was induced by 90 mins middle-cerebral artery occlusion (MCAO) 
in Sprague-Dawley rats, and LITA or control liposomes given intraperitoneally at occlusion 
and daily for up to two weeks post-MCAO. Magnetic resonance imaging (MRI) was used to 
estimate lesion volume at 24 h, 1 and 2 weeks post-MCAO and anterior lateral ventricular vol-
ume (ALVv) at 2 weeks post-MCAO. Locomotive behaviour was tested prior to the final MRI 
scan. After the final scan, brains were collected, and immunohistochemistry was performed. 
Results: Lesion volumes were decreased by ~80% from 24 h to one-week post-MCAO, in 
both control and LITA groups (P,0.05). However, the lesion was increased by ~50% over the 
subsequent 1 to 2 weeks after MCAO in the control group (from 24.1±10.0 to 58.7±28.6 mm3; 
P,0.05) but remained unchanged in the LITA group. ALVv were also attenuated by LITA 
treatment at 2 weeks post-MCAO (177.2±11.9% and 135.3±10.9% of contralateral ALVv for 
control and LITA groups, respectively; P,0.05). LITA-treated animals also appeared to have 
improved motor activity, moving with greater average velocity than control animals. Microglial 
immunoreactivity was ~40% lower in the LITA group compared to the control group (P,0.05), 
but LITA did not modulate neurogenesis, apoptosis, histone acetylation and lipid peroxidation. 
Conclusion: LITA appears to attenuate the harmful chronic neuroinflammation observed dur-
ing brain remodeling after a focal ischemic insult.
Keywords: ischemic stroke, acetate, liposomes, neuroinflammation, microglia, mid-cerebral 
artery occlusion
Introduction
Ischemic stroke is caused by obstruction of an artery to the brain from in situ thrombus, 
or an embolus from another artery or the heart, and one of the main causes of disability 
in industrialized countries.1 The use of recombinant tissue plasminogen activator 
(rtPA) that breaks down blood clots has significantly improved the morbidity of isch-
emic stroke.2 However, its use remains limited, as rtPA must be administered within 
4.5 hours of symptoms and so only 3%–8% of all patients are eligible for therapy.3,4 
In addition, thrombolytic treatment may lead to death due to intracranial hemorrhage.5
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On induction of ischemia, the sudden lack of oxygen 
and glucose elicits a cascade of pathological events includ-
ing abnormal recruitment of inflammatory cells, excess 
production of free radicals, initiation of pathological 
apoptosis, excessive glutamate excitotoxicity, and ion 
dyshomeostasis.6 Many of the pathological processes are 
mediated by mitochondrial dysfunction including increased 
lipid peroxidation leading to oxidative stress and apoptosis.7
Rapid neuronal death ensues in the immediate vicinity of 
ischemia, but around this initial infarcted area or ischemic 
core is the penumbra which is hypo-perfused with collateral 
blood flow maintaining some cellular functions. The penum-
bra is not passively dying over time but also actively recov-
ering sometime after induction of ischemic stroke8 and the 
concept of the penumbra lengthens the therapeutic window. 
Thus, treatments to enhance the brain’s own regenerative 
capacities, eg, by neurotrophic factors and cell replacement 
by transplantation have been proposed.9
Neuroinflammation progresses from hours to days fol-
lowing induction of ischemic stroke and is characterized by 
microglial activation and infiltration of circulating inflam-
matory cells.10 Microglia are activated following ischemic 
stroke, changing shape and phenotype, becoming amoeboid 
with shorter and thickened processes, and are comparable to 
macrophages in systemic inflammation. Activated microg-
lia can phagocytose pathogens and necrotic cells, suppress 
inflammation, and aid in brain repair.11 They also produce 
cytokines, both cytotoxic or cytoprotective,12 as well as 
matrix metalloproteinases (MMPs). MMPs disrupt the 
blood–brain–barrier (BBB) and allow peripheral leukocytes 
to infiltrate into the brain, exacerbating neuroinflammation 
and brain damage.13 Thus, systemic inflammatory status, prior 
to and at the time of stroke, is a major factor determining 
acute outcome as well as long-term prognosis.14
Anti-inflammatory treatments have been shown 
to reduce infarct size and improve neurological function,15 
eg, overexpression of the anti-inflammatory cytokine IL-10 
and treatment with anti-inflammatory, insulin-like growth 
factor reduced infarct volumes16 and attenuated motor-
sensory dysfunction.17 Propofol, another anti-inflammatory 
agent, has been shown to inhibit microglia-mediated inflam-
mation in a rat model of ischemic stroke, again reducing 
infarct volume and improving neurological functions.18 
Nafamostat mesilate, commonly used for treating inflam-
matory diseases such as pancreatitis, has been demonstrated 
to decrease infarct size and expression of pro-inflammatory 
mediators and promotes expression of anti-inflammatory 
molecules in transient middle cerebral artery occlusion 
(MCAO) in rats.19
Short chain fatty acids including acetate have been 
shown to attenuate inflammation.20 To the best of our 
knowledge, the effects of acetate have not been tested 
in experimental models of stroke. We hypothesized that 
acetate supplementation may attenuate the detrimental 
inflammation following induction of ischemia and pro-
tect the brain from further damage after the initial insult. 
However, while acetate in the form of calcium acetate is 
approved to control high blood phosphate levels in kidney 
disease,21 its half-life is short and induces gastrointestinal 
irritation.22 Thus, we propose the administration of acetate 
encapsulated within a liposome nanoparticle, liposome-
encapsulated acetate (LITA) to extend the half-life of 
acetate, as well as achieve a high payload with minimum 
toxicity.23 LITA has a polyethyleneglycol (PEG) coating to 
attenuate its clearance from the systemic circulation by the 
reticuloendothelial system.24 Furthermore, encapsulation 
of therapeutic compounds in liposomes has been shown 
to enhance therapeutic effects of drugs by providing an 
“inert” local environment to maintain their stability as well 
as prolong their blood residence time and thereby increase 
bioavailability to brain tissue.25,26
In this study, we assessed if administration of LITA 
attenuates brain injury following ischemic stroke induced by 
MCAO. We performed MRI to longitudinally assess infarct 
volume at 24 hours, 1 and 2 weeks post-MCAO: T2-weighted 
MRI is commonly used to serially assess infarct size.27 Loco-
motion in an open arena was also assessed as a surrogate 
measure of recovery prior to the last MRI scan. After the final 
scan, brains were harvested, and immunohistochemistry was 
performed to evaluate mitochondria, neurogenesis, apoptosis, 
and lipid peroxidation to assess the effects of acetate patho-
logical processes in stroke. Histone H3 acetylation was also 
measured as acetate action may be mediated via epigenetic 
modulation by acetate acetylation of histones.
Materials and methods
animals and treatment
For biodistribution studies (In vivo distribution of liposomal 
nanoparticles section) of LITA, male C57Bl/6J mice (8–10 
weeks old, n=8; Harlan, UK) were obtained and allowed to 
acclimatize for 5–7 days prior to intravenous (iv) injection 
with 10 MBq [18F]fluorodeoxyglucose ([18F]FDG) or lipo-
somes encapsulated [18F]FDG (n=4/group).
To test the effect of LITA on ischemic stroke, male 
Sprague Dawley rats (230–250 g, n=20; Harlan) were obtained 
and allowed to acclimatize for 5–7 days prior to induction 
of MCAO (Induction of MCAO treatment section). Animals 


































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





receive LITA or liposome-encapsulated 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES, control).
All experimental procedures on mice and rats were per-
formed with ethical approvals from the local ethical review 
panels of Imperial College London and King’s College 
London, respectively, in compliance with the UK Home 
Office Animals Scientific Procedures Act 1986.
liposomal nanoparticles
Preparation of liposomes-encapsulated hePes 
(control) or lITa
Liposomes were prepared as previously described.23 
Briefly, liposomes containing N1-cholesteryloxycarbonyl-3, 
7-diazanonane-1,9-diamine, 1,2-distearoyl-sn-glycero- 
3-phosphocholine, cholesterol, 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) 
(DOPE-Rhodamine), and 1,2-distearoyl-sn-glycero-3-phos-
phoethanolamine-N-methoxy-(polyethylene glycol)-2000 
(DSPE-PEG2000), were purchased from Sigma-Aldrich Co. 
(St Louis, MO, USA) or Avanti Polar Lipids, Inc (Alabaster, 
AL, USA). LITA nanoparticles were prepared by the thin lipid 
film hydration method and formulated by initial hydration of 
appropriate thin lipid films with 1 M acetate, pH 2.3. Lipid 
suspensions were then sonicated (1 hour, 30°C, in the dark) 
before their pH were adjusted to 7.0 using sodium hydroxide 
(pH 12.0) or hydrochloric acid (pH 2.0) (Sigma-Aldrich Co.). 
The final preparations of nanoparticles were obtained follow-
ing extensive dialysis (Float-A-lyzer G2; Spectrum Labs, Los 
Angeles, CA, USA) over 18 hours with changes of deionized 
water every 4–5 hours. Corresponding control (no acetate) lipo-
somes were prepared similarly except thin lipid film hydration 
was performed using 4 mM HEPES, pH 6.5, 135 mM sodium 
chloride. Final LITA and control nanoparticle sizes were deter-
mined using a Zetasizer (Malvern Instruments, Malvern, UK).
The formulation of control nanoparticles and LITA was 
chosen based on extensive testing of a variety of differ-
entially formulated liposomes. The aim was to synthesize 
nanoparticles of good size (100 nm), possess in vitro stability 
and maximal acetate encapsulation.23 We showed acetate 
was stably encapsulated in LITA for well over a week 
in vitro,28 but we were unable to assess acetate release from 
LITA in vivo. LITA-type nanoparticles were synthesized 
encapsulating 13C-acetate to enable detection by 13C-nuclear 
magnetic resonance spectroscopy. We were unable to detect 
liposomal release of 13C-acetate into the blood following 
systemic administration; indeed, we were not even able to 
detect the equivalent unencapsulated 13C-acetate dose (Brody 
et al, unpublished results). However, this is unsurprising 
as basal acetate concentrations in rodents (and some 
humans) are ~100 uM25 and our acetate doses are ~4.5 uM. 
Furthermore, the injected dose would have been diluted in 
the overall circulation of the body following administration.
Different formulations also produce varying sized 
liposomes. We aimed to formulate liposomes of ~100 nm, 
a nanoparticle size previously shown to be optimal for 
prolonged in vivo circulation of PEGylated liposomes,28 
to enhance liposomal uptake by the brain. In summary, the 
final choice of liposomal nanoparticle balanced the optimal 
size for increased in vivo circulation time while achieving 
optimal and stable encapsulation of acetate.
In vivo biodistribution of liposomal nanoparticles
Real-time biodistribution of the liposomal nanoparticle was 
assessed by micro positron emission tomography-computer-
ized tomography (PET-CT; Siemens, Forchheim, Germany). 
Liposomes were formulated as described above but with [18F]
FDG during hydration of the thin lipid films, ensuring a dose 
of 10 MBq of [18F]FDG encapsulation per 200 µL injection. 
Mice were anesthetized with 2%–2.5% isoflurane, 1 L/min 
oxygen and received iv injection of either 10 MBq [18F]FDG 
or liposome-encapsulated-[18F]FDG (n=4/group) and PET-CT 
images acquired for 30 minutes.26 PET signal intensities were 
obtained from an appropriate region of interest (ROI) in the 
brain at different times after dosing to provide standard uptake 
value (SUV) curves. The area under the curve (AUC) was 
calculated from the SUV curves to estimate uptake of [18F]
FDG and liposome-encapsulated-[18F]FDG into the brain.
rat model of McaO
Induction of McaO and treatment
For the induction of MCAO, rats were anesthetized with 2% 
isoflurane, oxygen–air mix (30:70). A midline incision was 
made to expose the common carotid artery. A 4-0 monofila-
ment nylon suture (Doccol Corporation, Sharon, MA, USA) 
with a silicone rubber coated tip (0.33 mm diameter, 4–5 mm 
long) was introduced into the right external carotid artery 
and advanced along the inner carotid artery until 10 mm past 
the carotid canal which insured blockage of the origin of the 
middle cerebral artery (MCA) as previously described.29 An 
intraperitoneal (ip) injection (1 mL/300 kg body weight) of 
HEPES encapsulated liposomes (control group) or LITA 
(264.82 µg/mL, 4.41 mM) was given at occlusion. Animals 
were then allowed to recover from anesthesia during MCAO. 
After 90 minutes of MCAO, animals were re-anesthetized, and 
the filament was retracted completely to allow reperfusion of 
the MCA. Saline (3 mL) was given subcutaneously to attenu-
ate possible dehydration. Body temperature was maintained 
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Animals were also given an ip dose of either control 
(1 mL/300 kg) or LITA nanoparticles (1 mL/300 kg) daily for 
up to 2 weeks after MCAO. MRI was performed at 24 hours, 
1 and 2 weeks post-MCAO (Magnetic resonance imaging sec-
tion) to estimate infarct volume as well as the anterior lateral 
ventricular volume (ALVv) which increases with increasing 
infarct volume. Locomotion (average velocity and distance 
traveled) in an open arena (Locomotive behavior section) was 
assessed as a surrogate measure of motor recovery before the 
final MRI scan. Body weights were also recorded daily before 
the surgery (baseline) and then daily for 2 weeks after MCAO.
After the final MRI scan, brains were perfusion-fixed with 
4% paraformaldehyde (PFA, PBS), harvested, and immersed 
in 4% PFA for a week, prior to storage in PBS until place-
ment in 30% sucrose (PBS) for subsequent cryosectioning 
and immunofluorescence (Immunofluorescence microscopy 
section). Immunofluorescence was performed using primary 
antibodies for astrocytes (GFAP), microglia/macrophage 
(Iba1), mitochondrial density (MTCO1), lipid peroxidation 
(MDA), general proliferation (Ki67), neurogenesis (nestin), 
histone modification (acetylated histone H3), and apoptosis 
and neurodegeneration (appoptosin). (Iba1 does not distin-
guish between microglia and macrophages infiltrating the 
brain from the periphery).
Magnetic resonance imaging
Rats were anaesthetized with isoflurane, oxygen-air 
(30%:70%) mix. The rat head was carefully located centrally 
in a 43 mm inner diameter quadrature volume MRI coil and 
then placed within the magnet bore of a 7T MR scanner 
(Agilent Technologies, Santa Clara, CA, USA). T2-weighted 
MRI was performed using a fast spin-echo sequence with 
repetition time (TR), 4,000 ms; effective echo time (TE), 
60 ms; echo train length, 8; four averages; 24 contiguous 
coronal slices (1 mm thick) were recorded of the whole rat 
brain with field of view, 32×32 mm and matrix size, 128×128.
Infarct volumes on the T2-weighted MR images were 
manually segmented using ImageJ (1.46 r, National Institutes 
of Health (NIH), Bethesda, Maryland, USA) at 24 hours, 
1 and 2 weeks after MCAO. The circumference of the ven-
tricle wall on the ipsilateral (stroke side) and contralateral 
sides were measured from three to five sections per animal at 
the level of striatum at two weeks after MCAO to provide the 
ALVv and expressed as a mean percentage of the ipsilateral 
side to the contralateral one.
locomotive behavior
The open field test was performed to evaluate locomotor 
activity at 10 days after MCAO. Behavioral testing was 
carried out in a quiet and dimly lit behavior room in white 
featureless arenas. Rats were individually placed in the 
arena, and their behavior was recorded for 30 minutes via a 
video camera positioned on the ceiling, directly above the 
arenas. The total distance covered by the rat and the aver-
age velocity was measured using EthoVision XT software 
(Noldus, Wageningen, the Netherlands). After the end of the 
recording, animals were returned to their cages and the arenas 
were thoroughly cleaned with 70% industrial methylated 
spirit solution between each set of animals.
Immunofluorescence microscopy
Coronal brain sections (20 µm thick) were sectioned 
using a freezing microtome (Carl Zeiss Meditec AG, Jena, 
Germany), collected onto positively charged slides, and 
stored at -20°C until use. Three to five sections per animal 
(spaced 200 µm apart) were used for each antibody, between 
the levels of the anterior and posterior striatum. Single- and 
double-immunofluorescence was performed with a few 
modifications as previously described.30 Briefly, sections 
were incubated in 10% horse serum in Tris-buffered saline 
(pH 7.4) plus 0.1% Triton X-100 (TBS+) for 2 hours at 
room temperature prior to incubation in 2% horse serum in 
TBS+ containing either single or combinations of primary 
antibodies: rabbit polyclonal anti-Ki67 (clone sp6, 1:200; 
Thermo Fisher Scientific, Waltham, MA, USA) and mouse 
monoclonal anti-nestin (rat 401, 1:90; Developmental 
Studies Hybridoma Bank, Iowa City, IA, USA); rabbit poly-
clonal anti-GFAP (1:5,000; Dako Denmark A/S, Glostrup, 
Denmark) and mouse monoclonal anti-NeuN (1:500; 
EMD Millipore, Billerica, MA, USA); rabbit polyclonal 
ionized calcium-binding adaptor (Iba1, 1:1,500; Wako 
Pure Chemical Industries, Ltd., Osaka, Japan); rabbit 
polyclonal anti-appoptosin (SLC25A38, 1:250; Sigma-
Aldrich Co.); rabbit polyclonal anti-accHH3 (1:300; EMD 
Millipore); mouse MTCO1 (1:100) and rabbit polyclonal 
anti-MDA (1:250; both from Abcam, UK) at 4°C overnight. 
After washes, sections were incubated in the appropriate 
secondary fluorescent antibodies (1:1,000, Alexa products; 
Thermo Fisher Scientific) diluted in TBS+ for 2 hours at 
room temperature. After washes in TBS+ (×2) and TBS–
buffers (the former containing Hoescht33258 as a counter-
stain), slides were mounted using Fluorsave (Calbiochem, 
UK). For negative control, either the primary or the second-
ary antibodies were omitted to reveal non-specific labeling.
Mean immunopositive cell numbers (Ki67) and mean 
percentage of area of immunoreactivity (GFAP, Iba1, nestin) 
were measured in three separate optical fields per section 
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MDA, and accHH3, an estimation of the immunoreactivity 
was performed in the whole of the peri-infarct area by scoring 
from 0 (no immunoreactivity) to 5 (very high immunoreac-
tivity). Each optical field photo was taken under identical 
conditions using a Zeiss AxioImager fluorescent microscope 
(Carl Zeiss Meditec AG) and measurements were performed 
using the ImageJ software after applying an appropriate 
threshold level (1.46 r; NIH).
statistical analysis
A mixed design ANOVA was applied to determine dif-
ferences in body weight and infarct size followed by least 
significant differences post-hoc analysis. Differences in the 
immunofluorescence and ALVv data between the groups 
receiving control or LITA were tested using Student’s 
unpaired t-test. Multiple regression analysis was also applied 
with treatment group and infarct size at 24 hours after 
MCAO as independent variables, to determine predictors of 
body weight, immunofluorescence findings, behavior, and 
percentage changes in infarct size (24 hours to 1 week and 
1–2 weeks after MCAO) and percentage ALVv at 2 weeks 
post-MCAO). Differences were considered significant if 
P,0.05, and IBM SPSS software (version 21) was used for 
all testing. All values presented are mean ± standard error 
of mean (SEM).
Results
Biodistribution of liposomal nanoparticle
Control liposomes and LITA were measured to be sized 
95.9±9.0 nm and 102.3±7 nm, respectively. In vivo bio-
distribution of the liposomal nanoparticle was determined 
by in vivo PET-CT imaging of [18F]FDG-encapsulated in 
liposomal nanoparticles, injected iv in normal mice. Uptake 
of the nanoparticle was observed in several organs includ-
ing the liver, heart, kidneys, and pancreas (Figure 1A–C). 
While uptake of liposome-encapsulated [18F]FDG into the 
brain was observed, uptake was significantly lower than 
that for non-encapsulated [18F]-FDG (SUV, P,0.01; AUC, 
P,0.001; Figure 1D and E).
Body weight
Body weights were similar in the two groups following 
MCAO, decreasing rapidly and remaining low for approxi-
mately a week before steadily increasing (Figure S1). Treat-
ment group and lesion volume at 24 hours after MCAO 
statistically significantly predicted the body weight at 2 weeks 
after MCAO (F(2,14)=5.798, P=0.015, R2=0.375; Table 1), 
but only lesion volume at 24 hours significantly contributed 
to the prediction (P=0.004, Table 1).
regional brain volumes by MrI
Infarct volume
MCAO led to infarct in the striatal-cortical region and 
appeared hyperintense with occasional small hypointense 
areas from necrosis by MRI (Figure S2). Infarct volumes 
were reduced by 85% and 83% in the first week after MCAO 
in control and LITA groups, respectively (P=0.002 and 
0.031, respectively; Figure 2). Similarly, infarct volumes 
remained lower at 2 weeks compared to that at 24 hours 
after MCAO for both control and LITA groups (55% and 
83% reduction, both P=0.001). However, while the infarct 
volume increased by 24.3% over 1–2 weeks after MCAO 
in the control group (P=0.031, Figure 2), the infarct volume 
during this time were essentially unchanged in the LITA 
group (P=0.982, Figure 2).
Treatment group and infarct size at 24 hours after MCAO 
significantly predicted the percentage change in infarct 
volume over 1–2 weeks after MCAO (F(2,14)=35.964, 
P=3×10-6, R2=0.814; Table 2). Both LITA treatment and the 
infarct volume at 24 hours after MCAO added significantly to 
the prediction (P=0.049 and P=2×10-7, respectively; Table 1).
anterior lateral ventricular volume
Expansion of the ALVv ipsilateral to the stroke arises from 
the shrinkage of the striatal-cortical areas due to infarction 
and so can be considered a measure of brain damage. The 
percentage of the ALVv ipsilateral to the stroke lesion rela-
tive to the contralateral ALVv was significantly higher in the 
control compared to the LITA group at 2 weeks post-MCAO 
(177.2%±11.9% and 135.3%±10.9%, respectively, P=0.020; 
Table 2). Both treatment group and infarct volume at 24 hours 
post-MCAO predicted the increase in ALV ipsilateral to 
the stroke (F(2,14)=6.068, P=0.013, R2=0.388; Table 2) but 
only the treatment group added significantly to the predic-
tion (P=0.033).
locomotive behavior
In open field behavior testing, the LITA group moved 
at greater velocity (17%) than those in the control group 
(P,0.05; Figure 3A; Table 2). The former also traveled 
greater distances than the latter, although significance was not 
quite reached (Figure 3B; 17%, P=0.054). Multiple regres-
sion analysis revealed that the prediction of motor recovery 
almost reached significance for the treatment group (P=0.057 
and 0.059 for velocity and distance traveled; Table 1).
Immunofluorescence
Neuroinflammation
Neuroinflammation at 2 weeks after MCAO was assessed 
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GFAP to visualize microglia/macrophages and astrocytes, 
respectively, which are increased/activated during neuro-
inflammation (Figure 4A and B). Percentage microglia/
macrophages immunoreactivity 2 weeks after MCAO was 
lower in the LITA group compared to the control group 
(38.18%, P=0.031; Table 2). Furthermore, treatment and 
infarct volume at 24 hours after MCAO significantly pre-
dicted the change in Iba1 immunoreactivity in the ipsilateral 
region to the stroke (F(2,12)=5.355, P=0.022, R2=0.384; 
Table 1), although neither factor added significantly to the 
prediction. Astrocytosis appeared similar in both control 
and LITA groups (Table 2), although there was a trend of 
lower percentage GFAP immunoreactivity in the peri-infarct 
region in the latter animals (Figure 4B). Treatment group and 
infarct volume at 24 hours after MCAO did not predict the 
changes in astrocytosis at 2 weeks after MCAO (Table 1). 
Neuroinflammation at 2 weeks after MCAO appeared to be 
mediated by microglia rather than astrocytes in the transient 
ischaemia MCAO rat model.
Mitochondrial density
Mitochondrial dysfunction mediates many of the pathological 
processes during ischemic stroke. To assess the effect of 
LITA on mitochondria, 2 weeks after MCAO, the mito-
chondria density was estimated in the peri-infarct area using 
the MTC01 antibody (reacts with cytochrome c oxidase 
subunit-1, a key mitochondrial enzyme). Mitochondria 
density was comparable in both control and LITA groups 
(Table 2; Figure S3) and not predicted by treatment group or 
infarct volume at 24 hours after MCAO (Table 1).
Figure 1 Biodistribution of liposomal nanoparticles. 
Notes: representative (A) positron emission tomography (PeT); (B) computerized tomography (cT); (C) PeT-cT fusion images at 30 minutes after an intravenous (iv) 
injection of 200 µl liposome-encapsulated [18F]fluorodeoxyglucose ([18F]FDg) in normal mice; (D) brain standard uptake value (sUV) curves measured for 30 minutes after 
iv injection of [18F]FDg or liposome-encapsulated [18F]FDg; and (E) area under curve (aUc) of brain sUV curves. Values are presented as mean ± standard error of mean. 

















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





as MDA. MDA immunoreactivity at the peri-infarct area 
was shown to be similar between control and LITA groups, 
although generally lower in the latter (Table 2; Figure S3). 
However, treatment group and infarct volume at 24 hours 
after MCAO significantly predicted the degree of MDA 
immunoreactivity in the peri-infarct area (F(2,14)=14.87, 
P=0.001, R2=0.665) with the infarct volume at 24 hours 
after MCAO significantly added to the prediction (P=0.0002, 
Table 1), but not the treatment.
Proliferation
Cell proliferation, as assessed by Ki67 immunoreactivity, 
was similar in both control and LITA groups, although 
there appeared to be a trend for fewer proliferating cells in 
the latter (Table 2; Figure S3). Treatment group and infarct 
volume at 24 hours after MCAO significantly predicted 
numbers of proliferating cells ipsilateral to the stroke lesion 
(F(2,12)=9.282, P=0.004, R2=0.542), with the infarct volume 
at 24 hours after MCAO statistically significantly adding to 
the prediction (P=0.002; Table 2).
endogenous neurogenesis
Nestin is expressed by neuronal progenitor cells. Nestin 
immunoreactivity was similar between the control and LITA 
3 3  7LPHSRVW0&$2/HVL
RQYROXPHPP

KRXUV ZHHN ZHHNV KRXUV ZHHN ZHHNV
3 3 3 
&RQWUROOLSRVRPHV /,7$
Figure 2 MrI assessment of infarct volumes in rats treated with control or liposomal 
encapsulated acetate (lITa) at 24 hours, 1, and 2 weeks after middle-cerebral artery 
occlusion (McaO). 
Note: Values are presented as mean ± standard error of mean.
Table 1 Multiple regression analysis with treatment group and infarct size at 24 hours after mid-cerebral artery occlusion (McaO) 
as independent variables




Infarct size (24 hours 
post-MCAO), P-value
Body weight (2 weeks McaO) F(2,14)=6.117, P=0.012*, r2=0.393 0.803 0.004**
Volumes by MRI
Percentage change in infarct volume over 24 hours to 
1 week post-McaO
F(2,14)=4.677, P=0.028*, r2=0.315 0.25 0.001***





anterior lateral ventricle size at 2 weeks post-McaOa F(2,14)=6.068, P=0.013*, r2=0.388 0.033* 0.051
Locomotive behavior at 10 days post-MCAO
average velocitya F(2,12)=2.158, P=0.152, r2=-0.126 0.057 0.778
Total distance traveleda F(2,14)=2.105, P=0.159, r2=0.121 0.059 0.772
Immunofluorescence at 2 weeks post-MCAO
astrocytosis (gFaP immunoreactivity)a F(2,12)=0.903, P=0.429, r2=-0.013 0.699 0.231
Microgliosis (Iba1 immunoreactivity)a F(2,12)=5.355, P=0.022*, r2=0.384 0.064 0.051
Mitochondria density (MTcO1 immunoreactivity)a F(2,14)=-0.634, P=0.545, r2=-0.048 0.410 0.399
lipid peroxidation (MDa immunoreactivity)a F(2,12)=14.87, P=0.001***, r2=0.665 0.66 0.0002***
cell proliferation (Ki67 immunoreactivity)a F(2,12)=9.282, P=0.004**, r2=0.542 0.418 0.002**
Neuronal progenitors (nestin immunoreactivity)a F(2,12)=0.399, P=0.680, r2=-0.094 0.635 0.526
histone h3-acetylation (acchh3 immunoreactivity)a F(2,12)=9.136, P=0.004**, r2=0.538 0.649 0.001***
apoptosis (appoptosin immunoreactivity)a F(2,12)=7.661, P=0.007**, r2=0.488 0.942 0.002**
Notes: Values are mean ± standard error of mean. Significance level *, **, ***, and ****; P,0.05, 0.01, 0.001, and 0.00001, respectively. aMeasurement of the peri-infarct 
area ipsilateral to the stroke lesion at 2 weeks post-middle-cerebral artery occlusion (McaO), expressed as a percentage of the same measure from the corresponding area 
contralateral to the stroke.
lipid peroxidation
Following induction of transient ischemia, the restoration 
of oxygen to the brain leads to elevated ROS and increased 
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groups, although a trend to lesser immunoreactivity in the 
latter was observed (Table 2; Figure S3), suggesting similar 
neurogenesis between the two groups. The degree of neuro-
genesis was not predicted by the treatment group or infarct 
volume at 24 hours after MCAO (Table 1).
histone h3 acetylation
Possible epigenetic modulation arising from LITA was inves-
tigated by measuring the degree of histone H3 acetylation. 
Acetylated histone H3 (accHH3) immunoreactivities were 
similar between the control and LITA groups at 2 weeks 
after MCAO (Table 2; Figure S3). However, treatment 
group and infarct volume at 24 hours after MCAO signifi-
cantly predicted accHH3 immunoreactivity (F(2,14)=9.136, 
P=0.004, R2=0.538), but only the infarct volume statistically 
significantly contributed to the prediction (P=0.001, Table 1).
apoptosis (appoptosin)
Apoptosis (indicated by appoptosin immunoreactivity) in the 
peri-infarct area was similar in both the control and LITA 
Table 2 Infarct volume at 24 hours, 1, and 2 weeks post middle-cerebral artery occlusion (McaO)
Measurement Control LITA
Volumes by MRI
Infarct volume at 24 hours post-McaO (mm3) 130.0±41.6 94.5±35.7
Infarct volume at 1 week post-McaO (mm3) 24.1±10.1 16.1±6.1
Infarct volume at 2 weeks post-McaO (mm3) 58.7±28.6 15.7±7.6
anterior lateral ventricle volumea 177.2±11.90 135.3±10.9*
Locomotive behavior at 10 days post-MCAO
average velocity (cm/s) at 10 days post-McaO 15.94±0.57 18.64±1.29*
Total distance traveled (cm) at 10 days post-McaO 4,559.4±166.8 5,325.3±370.0
Immunofluorescence at 2 weeks post-MCAO
gFaP immunoreactivitya 1,088.7±691.7 952.5±367.2
Iba1 immunoreactivitya 2,134.3±842.5 1,319.4±444.8*
Nestin immunoreactivitya 1.50±0.38 1.18±0.27
MTcO1 immunoreactivitya 189.08±24.07 165.23±19.16
Ki67 immunoreactivitya 3.64±1.13 2.11±0.45
appoptosin immunoreactivity score 2.24±0.37 2.21±0.38
MDa immunoreactivity score 2.36±0.52 1.70±0.67
acetylated-h3 immunoreactivity score 1.68±0.47 1.55±0.54
Notes: Percent of anterior lateral ventricle of ipsilateral relative to the contralateral region to the stroke, immunofluorescence measurements at 2 weeks post-MCAO in 
rats treated with and without liposomal encapsulated acetate (lITa). Values are mean ± standard error of mean; *P,0.05. aMeasurement of the peri-infarct area ipsilateral 










Figure 3 locomotive behavior: (A) average velocity and (B) distance traveled of rats treated with control or liposomal encapsulated acetate (lITa) at 10 days after 
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groups at 2 weeks after MCAO (Table 2; Figure S3) and 
can be predicted from group and infarct volume at 24 hours 
post-MCAO (F(2,14)=7.661, P=0.007, R2=0.488); the infarct 
volume statistically significantly added to the prediction 
(P=0.002, Table 1).
Discussion
MCAO leads to irreversible cell damage in the immediate brain 
area and is known to induce a cascade of pathophysiological 
processes in the penumbra leading to cell death and increasing 
infarct volume sometime after the insult.6 In our study, LITA 
appears to protect the penumbra from entering irreversible 
cell death by preventing further increases in the volumes of 
the infarct 1–2 weeks after MCAO and the ALVv at 2 weeks 
post-MCAO. Locomotor behavior testing at 10 days after 
MCAO suggests greater motor recovery in the LITA group. 
Neuroprotection of the penumbra by LITA appears to be due to 
attenuated neuroinflammation mediated by microglia. Lipid per-
oxidation, proliferation, endogenous neurogenesis, histone H3 
acetylation, and apoptosis were similar between the control 
and LITA groups but were dependent on the infarct volume 
24 hours after MCAO, which was relatively variable between 
animals in our 90 minutes transient ischemia MCAO rat model.
We have previously shown that LITA nanoparticles can 
effectively modulate metabolic processes associated with 
mitochondrial function and lipid metabolism in peripheral 
healthy tissues and ectopic tumors.23,31 LITA has been 
shown to attenuate peripheral inflammatory responses,23 and 
Wang et al19 have demonstrated significant contribution of 
the periphery to MCAO-induced brain damage. Here, we 
extend this work to show that these nanoparticles can also 
have beneficial effects on cerebral tissue following MCAO. 
Cationic liposomes have been shown to enter the brain 
by absorptive-mediated endocytosis.32 Using [18F]FDG to 
estimate the in vivo biodistribution of liposomal payloads, 
we show that not much of the [18F]FDG encapsulated in 
our liposomal nanoparticles can enter the brain of normal 
mice. However, induction of MCAO has been shown to 
significantly disrupt the BBB for up to 4 weeks following 
reperfusion.33 Furthermore, increased BBB permeability has 
an “enhanced permeability and retention effect”,34 similar to 
that observed in tumors,31 during which considerable uptake 
of LITA into the brain may occur; a recent review reports 
the brain accumulation of liposomes in experimental stroke 
models.35 In addition, LITA are significantly PEGylated, 
which prolongs their circulation time, resulting in preferential 
accumulation at sites of leaky vasculature such as tumors 
or brain tissue following BBB disruption. We do note that 
determining nanoparticle distribution by [18F]FDG PET could 
be slightly misleading as [18F]FDG may be released from the 
circulating liposomes. However, using [18F]FDG to estimate 
in vivo distribution of liposomal payloads in normal mice, 
we show there is little [18F]FDG in the brain, consistent with 
our previous studies using similar, but fluorescent-labeled 
liposomes.25 In addition, we show non-encapsulated [18F]
FDG better penetrate the brain than encapsulated [18F]FDG, 
suggesting cargo release from liposome nanoparticles to 
be minimal.
The neuroprotective action of LITA is likely to arise 
from attenuation of the detrimental effects of the microglia/
macrophage activation following MCAO, as LITA did not 
modulate lipid peroxidation, endogenous neurogenesis, 
histone H3 acetylation, or apoptosis following ischemic 
insult. Also, LITA treatment prevented the increase in 
the infarct volume 1–2 weeks after MCAO, alongside an 
increase in the ALVv at 2 weeks post-MCAO, suggesting 
the beneficial effects of LITA are only evident sometime 
after the initial injury. Thus, LITA may have the advantage 
over rtPA by being effective after the initial ischemic insult.
Microglia and macrophages exhibit either M1 or M2 
phenotypes. M1 microglial/macrophages usually release 







Figure 4 Immunofluorescence micrographs of (A) Iba 1 and (B) gFaP immuno-
reactivities in the peri-infarct area (ipsilateral to the stroke lesion) and the 
corresponding region in the contralateral hemisphere in control or liposomal 
encapsulated acetate (lITa)-treated animals at 2 weeks after middle-cerebral artery 
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lipopolysaccharide (LPS),36 whereas the M2 phenotype is 
activated by, eg, interleukin-4, and possess “neuroprotec-
tive” properties including enhanced phagocytic activity and 
reduced production of inflammatory mediators.37 Following 
induction of 60 minutes transient ischemia by MCAO, Hu 
et al37 showed that the majority of microglia/macrophages 
in the infarct were of the M2 phenotype, promoting cortical 
neuron survival. However, within a week of MCAO, the 
M2 phagocytic response was attenuated and M1 microglia/
macrophages dominated the injured area. Concomitant with 
the significantly lesser microglial/macrophage reaction at 
two weeks after MCAO in our study with LITA, and the 
known transition of microglia/macrophage from M2 to M1 
phenotype by this time, acetate may be attenuating the detri-
mental inflammation presided over by the M1 phenotype and 
protecting the penumbra from damage. We suggest a longer 
interventional period would be advantageous, considering 
brain tissue remodeling after stroke can occur for a protracted 
period of time following the primary ischemic event. Indeed, 
chronic brain tissue remodeling was evident even a year after 
a 2-hour transient ischemic insult in a rat model.38
The effects of LITA may be mediated by histone acetyla-
tion as histone hyper-acetylation has been shown to be anti-
inflammatory39 and can alter gene expression.40 Reisenauer 
et al41 were able to elevate brain acetate levels with oral 
glyceryl triacetate (GTA) to attenuate neuroglial activation 
in a model of LPS-induced neuroinflammation.42 In normal 
rats, GTA increased acetylation of certain histones includ-
ing H4 at lysine 8 but did not acetylate other histones41 and 
reversed the reduction in H3 acetylation in LPS-induced 
inflammation.43 We were unable to detect changes in histone 
H3 acetylation with LITA treatment, but this may be due 
to the insensitivity of our immunofluorescence methods 
and more sensitive Western blotting methods needs to be 
employed. Furthermore, in our study, acetate (LITA) treat-
ment was relatively short-term.
In the body, acetate can be generated in vivo by gut bac-
teria, from the digestion of resistant starches.22,44 Our study 
suggests that a diet rich in resistant starch or a ketogenic diet 
may be advantageous following stroke, consistent with previ-
ous reports.45 Indeed, we have shown that a high resistance 
starch-containing diet is able to modulate brain function in 
a normal mouse model.46 However, nutritional interventions 
may be insufficient to maintain adequate/prolonged circula-
tion of short-chain fatty acids to enhance their accumulation 
in the brain, which clearly can be achieved by encapsulation 
of acetate in PEGylated liposomes. Furthermore, delivery 
of acetate in nanoparticles provides the opportunity to 
modify these delivery agents to enhance brain targeting for 
therapeutic treatment of neurodegenerative disorders, eg, 
Alzheimer’s disease (AD), where the BBB is not as obviously 
disrupted as in our MCAO model.47 Inappropriate chronic 
microglial inflammation is a characteristic feature of many 
neurodegenerative diseases including AD30 and LITA may 
be a potential therapy for such diseases and further investiga-
tions are warranted.
Conclusion
We have shown that LITA appears to attenuate the harmful 
chronic neuroinflammation mediated by microglia/
macrophages during brain remodeling after a focal isch-
emic insult.
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Figure S1 Daily body weights of rats treated with control and liposome-encapsulated acetate (lITa) during the 2 weeks after middle-cerebral artery occlusion (McaO).&RUWH[
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Figure S2 Typical coronal in vivo T2-weighted magnetic resonance images of the brain at -0.10 Bregma of control and liposomal encapsulated acetate (lITa) treated rats 
at 2 weeks after middle-cerebral artery occlusion.
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Figure S3 Immunofluorescence for mitochondrial density (MTCO1), lipid peroxidation (malondialdehyde, MDA), neural progenitors (nestin), proliferation (Ki67), histone 
h3 acetylation (acchh3), and appoptosis (appoptosin) in control or liposomal encapsulated acetate (lITa)-treated animals at 2 weeks after middle-cerebral artery occlusion.
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